Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of April 2026. The report discloses the entry into a material definitive agreement regarding a private placement of equity securities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial metric disclosed relates to the capital raise:
- Aggregate Gross Proceeds: Approximately $760,000 (before deducting offering expenses).
- Shares Issued: 2,000,000 Class A Ordinary Shares.
- Implied Price per Share: $0.38.
Material Changes
On April 7, 2026, the Company entered into a Securities Purchase Agreement to sell and issue 2,000,000 Class A Ordinary Shares. This transaction is expected to close on April 9, 2026, subject to customary closing conditions. The shares were issued pursuant to a registration statement on Form F-3 filed in November 2025 and a prospectus supplement filed on April 9, 2026.
Guidance, Outlook, and Management Commentary
The Company intends to use the net proceeds from the Offering for general corporate purposes. No specific financial guidance, risk factors, or unusual items beyond the standard offering disclosures were detailed in this summary text.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $760,000 gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific investor rights, lock-up periods, or covenants.
- Confirm the exact amount of offering expenses to determine the net proceeds available for general corporate purposes.
- Check subsequent filings for the impact of this dilution on existing shareholders.